Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 5 de 5
Filtrar
Más filtros










Intervalo de año de publicación
1.
Afr J Med Med Sci ; 45(3): 291-297, 2016 Sep.
Artículo en Inglés | MEDLINE | ID: mdl-29462535

RESUMEN

BACKGROUND: Zinc has been reported to mediate cellular responses to injury by producing cytoprotection via the scavenging of reactive oxygen species. Anti-stress medications are generally anti-psychotic drugs and anti- depressants. Some Anti-psychotic drugs such as risperidone have been reported to possess anti-ulcer activity. Risperidone as an antipsychotic drug blocks several neurotransmitter systems including dopaminergic, adrenergic, histaminergic and serotonergic pathways. METHOD: The study investigated the antiulcer activity of Zinc Chloride (ZnCl(2)) in combination with risperidone in male Wistar rats. The animals were divided into two groups of twenty animals each for ZnCl(2) and risperidone groups. Each group was further divided into four subgroups. ZnCl(2) was administered orally at 20mg/kg, 40mg/kg and 80mg/kg to a subgroup, while 80mg/kg of ZnCl(2) was administered in combination with risperidone (0.1mg/kg, 0.3mg/kg and 0.5mg/kg) orally once daily for 21 days. The controls were treated with distilled water. Ulcer was induced using indomethacin. Histology of the stomach tissues was prepared with PAS and H& E stains. Ulcer score and ulcer area were assessed using standard methods. Data were analysed using student t-test and Graphpad Prism 5. RESULTS: There were decreases in ulcer scores using the different doses of ZnCl, (20mg/kg, 40mg/kg and 80mg/kg). Also using the highest dose ZnCl(2) (80mg/ kg) and different doses of risperidone there were decreases in ulcer scores compared to the control. This effect of the risperidone showed a significant dose- dependent reduction. The effect ZnCl(2), and risperidone were also reflected in the ulcer area and in the histology. CONCLUSION: These findings suggest that ZnCl(2), enhances the gastroprotective activity ofrisperidone in indomethacin- induced gastric ulcer. However, more detailed studies are necessary to confirm the relevance of this finding and its implications in clinical settings.


Asunto(s)
Cloruros/farmacología , Antagonistas de Dopamina/farmacología , Sustancias Protectoras/farmacología , Risperidona/farmacología , Úlcera Gástrica/tratamiento farmacológico , Estómago/efectos de los fármacos , Compuestos de Zinc/farmacología , Animales , Antiinflamatorios no Esteroideos/efectos adversos , Sinergismo Farmacológico , Indometacina/efectos adversos , Masculino , Ratas , Ratas Wistar , Úlcera Gástrica/inducido químicamente
2.
Niger J Physiol Sci ; 30(1-2): 33-7, 2015 Dec 20.
Artículo en Inglés | MEDLINE | ID: mdl-27506168

RESUMEN

Betulinic acid (BA) is a lupane-type triterpene that has been identified and isolated from various plant species used in ethnomedicine in various cultures across the world. This study was undertaken to elucidate the mechanisms underlying the anti-ulcer effect of Betulinic acid. The effect of BA on indomethacin-induced ulcer, gastric mucus secretion, gastric mucus cells count, basal and histamine-induced gastric acid secretion and levels of malondialdehyde formation were studied using dose of 0.5, 1.5, and 3.0 mg/kg. The results showed that BA reduced indomethacin-induced ulceration significantly and significantly increased  gastric mucus secretion in the 1.5 mg/kg and 3.0 mg/kg BA treated rats compared to the control rats. There was a significant increase  in the mucus cells count in all the treated groups which is in a dose- dependent manner compared to the control group. There was significant decrease  in gastric acid secretion in each of the BA treated groups compared to the control. Malondialdehyde concentration significantly decrease in all the treated groups compared to the control. The anti-gastric ulcer effect of BA may be mediated via decreasing gastric acid secretion, increasing gastric mucus secretions, increasing the number of gastric mucus cells and also by reducing the level of MDA concentration.


Asunto(s)
Antiulcerosos/uso terapéutico , Úlcera Gástrica/tratamiento farmacológico , Triterpenos/uso terapéutico , Animales , Antiulcerosos/farmacología , Relación Dosis-Respuesta a Droga , Ácido Gástrico/metabolismo , Mucosa Gástrica/efectos de los fármacos , Mucosa Gástrica/metabolismo , Masculino , Triterpenos Pentacíclicos , Ratas , Ratas Wistar , Úlcera Gástrica/patología , Resultado del Tratamiento , Triterpenos/farmacología , Ácido Betulínico
3.
Drug Res (Stuttg) ; 64(5): 236-9, 2014 May.
Artículo en Inglés | MEDLINE | ID: mdl-24203083

RESUMEN

Donepezil (DP) is the major drug currently used for enhancing memory function in patients with Alzheimer's disease (AD), an action ascribed to the elevation of central cholinergic neurotransmission. However, there are indications that DP may protect neurons against injury through the prevention of free radical-mediated neuroinflammation that has been implicated in the pathology of AD. Thus, this study was carried out to examine the effect of DP on memory impairment and on biomarkers of oxidative stress induced by scopolamine (SC) and lipopolysaccharide (LP) in mice.Mice were treated with DP (0.5-4 mg/kg, i. p.) 30 min prior to i. p. injection of SC or LP once daily for 7 days before assessing for memory function utilizing the Y-maze paradigm and levels of biomarkers of oxidative stress using standard biochemical procedures.DP (0.5-2 mg/kg) significantly reversed the memory impairment produced by SC (1 mg/kg) or LP (250 µg/kg) in mice, indicating memory enhancing effect. The increased brain levels of malondialdehyde (MDA) evoked by SC (1 mg/kg) or LP (250 µg/kg), was significantly inhibited by DP (0.5-4 mg/kg), suggesting antioxidant property. Further, DP (0.5-4 mg/kg) significantly inhibited glutathione (GSH) depletion caused by SC (1 mg/kg) or LP (250 µg/kg) in mice brains, which suggest free radical scavenging property.These findings suggest that DP has antioxidant effect, which might be playing a significant role in its memory enhancing activity in mice. However, more detailed studies are necessary to confirm the relevance of this finding and its implications in clinical settings.


Asunto(s)
Depuradores de Radicales Libres/farmacología , Radicales Libres/metabolismo , Indanos/farmacología , Trastornos de la Memoria/tratamiento farmacológico , Memoria/efectos de los fármacos , Piperidinas/farmacología , Animales , Antioxidantes/farmacología , Biomarcadores/metabolismo , Donepezilo , Glutatión/metabolismo , Lipopolisacáridos/farmacología , Masculino , Malondialdehído/metabolismo , Ratones , Estrés Oxidativo/efectos de los fármacos , Escopolamina/farmacología
4.
Afr J Med Med Sci ; 39 Suppl: 61-6, 2010 Dec.
Artículo en Inglés | MEDLINE | ID: mdl-22416645

RESUMEN

Calcium channel blockers (CCBs) are widely used as therapeutic agents, for the treatment of cardiovascular disorders. However, the discovery that CCBs bind to various regions of the brain suggest that they might also offer some beneficial effects in the treatment of neuropsychiatry disorders. This study was carried out to evaluate the anti-psychotic and sedative effects of two notable calcium channel blockers, verapamil and nifedipine in mice. The anti-psychotic effects of the CCBs were studied in the animal model of amphetamine-induced stereotyped behavioral disorders. The sedative effect was assessed utilizing the prolongation of the time of sleep, induced by thiopentone. The ability of CCBs to produce catalepsy in mice was also evaluated in the study. Graded doses of verapamil (5.0-20.0 mg/kg, i.p) significantly (p<0.05) suppressed stereotyped behaviour induced by amphetamine (10.0 mg/kg, i.p). In contrast, nifedipine (5.0-20.0 mg/kg, i.p) did not exhibit anti-psychotic effect, as it could not significantly reduce stereotypy caused by amphetamine. In the test for sedation, both verapamil (5.0-20.0 mg/kg, i.p) and nifedipine (10.0-20.0 mg/kg) significantly (p<0.05) prolonged the sleeping time induced by thiopentone (50.0 mg/kg, i.p). However, neither verapamil (5.0-20.0 mg/kg, i.p.) nor nifedipine (5.0-20.0 mg/kg, i.p.) at the tested doses produced any cataleptic behaviour in the animals. The results of the study suggest that verapamil has both anti-psychotic and sedative effects without inducing the side effect of catalepsy and might be relevant in the treatment of psychosis.


Asunto(s)
Antipsicóticos/farmacología , Bloqueadores de los Canales de Calcio/farmacología , Hipnóticos y Sedantes/farmacología , Nifedipino/farmacología , Psicosis Inducidas por Sustancias/tratamiento farmacológico , Verapamilo/farmacología , Anfetamina/efectos adversos , Animales , Bloqueadores de los Canales de Calcio/uso terapéutico , Catalepsia/inducido químicamente , Catalepsia/psicología , Modelos Animales de Enfermedad , Masculino , Ratones , Nifedipino/uso terapéutico , Psicosis Inducidas por Sustancias/psicología , Sueño/efectos de los fármacos , Conducta Estereotipada/efectos de los fármacos , Tiopental/efectos adversos , Verapamilo/uso terapéutico
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA